Google CEO sees newspaper future in advertising

April 8, 2009 03:35


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Google Inc.'s chief executive told newspaper publishers Tuesday that they should continue to rely on advertising but seek new ways to reach readers. Without providing specific recipes, Eric Schmidt laid out a few possibilities, including a site for medicine similar to the online encyclopedia Wikipedia, which lets users collectively contribute and edit entries. He urged publishers to focus on mobile technology and the development of new platforms for delivering news. Schmidt said there's still room for subscription and pay-by-the-piece journalism but he emphasized advertising, the source of 98 percent of Google's revenue, thanks to its success matching ads with a user's search terms and other keywords. "The important thing here is that advertising that is useful is going to work," he said.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection